How Much Weight Do You Lose with Ozempic?

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most studied weight loss medications available. Clinical trials demonstrate that patients taking semaglutide lose significantly more weight than those on diet and exercise alone, with average reductions ranging from 15% to 22% of initial body weight over a 68-week treatment period. Individual results depend on dose escalation, adherence, dietary choices, and metabolic factors unique to each person.

Clinical Trial Data: Average Semaglutide Weight Loss Results

The landmark STEP trials (Semaglutide Treatment Effect in People with obesity) tracked weight loss across multiple dose levels in non-diabetic patients. Participants receiving the highest maintenance dose (2.4 mg weekly) lost an average of 15.3 kg (roughly 10% of baseline weight) over 68 weeks when combined with lifestyle intervention. This represents one of the most robust clinical datasets for injectable GLP-1 therapy currently available.

Results improved significantly when patients remained on treatment and titrated to their target dose. Those who completed the full dose escalation phase and maintained consistency achieved weight loss reductions approaching 22% of baseline body weight in some cohorts. Notably, weight loss plateaued around week 20 for most participants, meaning continued treatment maintained the loss rather than producing unlimited additional weight reduction.

How Individual Factors Affect Your Weight Loss Outcome

Genetic variation in peptide pathways plays a measurable role in medication response. PlexusDx offers the Precision Peptide Genetic Test, which analyzes variants in key weight regulation genes such as GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313 to predict your metabolic predispositions. Testing after your first month of treatment helps optimize your therapy by identifying which compounds and dose strategies align with your genetic profile.

Beyond genetics, lifestyle integration determines real-world outcomes. Patients who combine semaglutide with reduced calorie intake and physical activity consistently outperform those relying on medication alone. Starting dose, titration speed, underlying metabolism, and medication adherence all influence the total percentage of weight lost. Age, baseline BMI, and presence of type 2 diabetes can also shift the expected magnitude of response.

Comparing Semaglutide to Other GLP-1 and Dual-Action Options

Semaglutide (a GLP-1 only compound) produces weight loss through appetite suppression and improved glucose regulation. Tirzepatide, a GLP-1/GIP dual receptor agonist, has demonstrated slightly higher average weight loss in head-to-head comparisons, with some participants losing 20–25% of body weight. PlexusDx also offers the GLP-Squared Injection, a compounded dual-agent option combining semaglutide and tirzepatide in one formulation for patients seeking optimized synergy.

Oral formulations of semaglutide deliver lower bioavailability than injections, which typically results in more modest weight loss outcomes—generally in the 10–16% range. Injectable semaglutide remains the most cost-effective entry point at PlexusDx, starting at $149/month, while dual-action injections begin at $249/month for patients ready to escalate their approach.

Setting Realistic Expectations: Timeline and Plateau Phases

Weight loss with semaglutide follows a predictable timeline. Most patients notice appetite reduction and modest weight changes within the first 2–4 weeks of starting therapy. Steady, measurable loss accelerates during weeks 4–12 as the dose escalates toward maintenance levels. By week 16–20, the rate of loss typically slows as your body adapts, and weight stabilizes at a new equilibrium.

Expecting continuous decline indefinitely sets unrealistic goals. Clinical data confirms that weight loss plateaus around 20 weeks for the majority of users; continued medication maintains this loss rather than producing additional pounds shed. Long-term success depends on treating semaglutide as a maintenance tool alongside lasting dietary and exercise habits. Discontinuing treatment without lifestyle support often results in gradual weight regain over months.

Getting Started with Semaglutide at PlexusDx

PlexusDx delivers compounded semaglutide injections prepared by licensed 503A compounding pharmacies to all 50 states without requiring insurance or membership fees. Your monthly cost remains flat at $149 regardless of dose level—your dose may need to go up, but your price won't. HSA and FSA funds are accepted, making treatment accessible to a broader range of patients.

After your first month on treatment, PlexusDx offers the optional Precision Peptide Genetic Test ($99 add-on) to identify your unique genetic predispositions across 14 metabolic pathways and 49 peptide targets. This insight allows your provider to refine your treatment plan, potentially switching to alternative compounds like tirzepatide or the dual GLP-Squared Injection if your genetic profile suggests superior response. Enrollment requires a brief online assessment and a telehealth consultation with a licensed PlexusDx clinician.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight will I lose if I take semaglutide?

Clinical trials show average weight loss of 15–22% of baseline body weight over 68 weeks with semaglutide. Your individual result depends on your starting dose, how high you titrate, lifestyle changes, and genetic metabolism. PlexusDx patients can take the Precision Peptide Genetic Test to understand their expected response based on key peptide-pathway variants.

How quickly does semaglutide produce weight loss?

Most patients notice reduced appetite within 1–2 weeks and measurable weight loss by week 4. The steepest decline typically occurs between weeks 4 and 20, with loss slowing thereafter as your body reaches a new equilibrium. Continued treatment maintains the loss rather than producing unlimited additional weight reduction.

Is semaglutide injections more effective than oral semaglutide for weight loss?

Yes. Injectable semaglutide delivers higher bioavailability and produces greater average weight loss (15–22%) compared to oral formulations (10–16%). PlexusDx semaglutide injections start at $149/month, making the more effective option also the most affordable entry point for GLP-1 therapy.

What happens if I stop taking semaglutide?

Weight loss is not permanent once semaglutide is discontinued. Most patients experience gradual weight regain over several months if they return to previous eating patterns. Long-term success requires combining medication with sustained dietary and lifestyle changes to prevent rebound.

Can genetic testing predict my semaglutide weight loss results?

PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence your metabolic response to GLP-1 compounds. Testing after your first month helps your provider optimize your dose or switch to tirzepatide or dual-action therapy if your genetics suggest superior response to those options.

Does PlexusDx semaglutide require insurance?

No. PlexusDx serves all 50 states without requiring insurance or membership fees. Semaglutide injections cost $149/month flat—your dose may increase, but your price won't. HSA and FSA accounts are accepted for added flexibility.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Ozempic For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.